Company intelligence / Profile preview

Suzhou BioMingsai Biopharmaceutical

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

BioMingsai is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the development of innovative therapies for autoimmune and inflammatory diseases. The company focuses on creating oral small molecule inhibitors that target cytokine pathways traditionally addressed by injectable biologics, such as the IL-17 pathway. Its lead candidate, BMS001, is an oral small molecule IL-17 inhibitor currently in Phase 2 clinical trials for plaque psoriasis. BioMingsai aims to provide patients with more convenient and accessible treatment options through its proprietary drug discovery platform.

Therapeutic areas: RheumatologyDermatologyImmunology
Modalities: Small moleculeAntibodyBiologic
Industry: Biotech

Beyond the preview

Go deeper on Suzhou BioMingsai Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou BioMingsai Biopharmaceutical.

Explore the full profile